Title  | Date  | Price  |
|---|
Infectious Diseases Drugs Markets
| Oct 2009 |
£2,050 |
Alzheimer's Disease New Drugs, Markets and Companies
| Oct 2009 |
£1,830 |
Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals), The
| Oct 2009 |
£2,135 |
Competitor Analysis: EGF-R Agonists and Antagonists
| Oct 2009 |
£270 |
Competitor Analysis: Her2 Receptor Antagonists
| Sep 2009 |
£225 |
Chinese Markets for Cervical Cancer Treatment Drugs
| Sep 2009 |
£2,440 |
World Neurodegenerative Diseases Market 2009-2024
| Sep 2009 |
£1,499 |
The Diabetes Market Outlook To 2014 Market Dynamics, Competitive Landscape, Emerging Therapies
| Sep 2009 |
£2,340 |
Chinese Markets for Brain Cancer Treatment Drugs
| Sep 2009 |
£2,440 |
Chinese Markets for Bladder Cancer Treatment Drugs
| Sep 2009 |
£2,440 |
Chinese Markets for Colon Cancer Treatment Drugs
| Sep 2009 |
£2,440 |
Current and Emerging Cancer Diagnostic Tests Emerging Assays and Companies Developing New Technologies and Products
| Sep 2009 |
£1,740 |
The Japanese Cancer Diagnostics Market
| Sep 2009 |
£3,475 |
Cancer Diagnostic Testing A Global Market Overview - Facilities, Test Volumes, and Sales Forecasts by Country
| Sep 2009 |
£395 |
The French Cancer Diagnostics Market
| Sep 2009 |
£2,500 |
The US Cancer Diagnostics Market
| Sep 2009 |
£4,510 |
Cancer Diagnostic Technologies Assessment of Current and Emerging Technologies, and Their Potential Market Applications
| Sep 2009 |
£1,035 |
Cancer Diagnostics Market New Product Development Opportunities, Market Penetration Strategies, Entry Barriers and Risks
| Sep 2009 |
£305 |
The Spanish Cancer Diagnostics Market
| Sep 2009 |
£2,500 |
The UK Cancer Diagnostics Market
| Sep 2009 |
£2,500 |
The German Cancer Diagnostics Market
| Sep 2009 |
£2,500 |
The Italian Cancer Diagnostics Market
| Sep 2009 |
£2,500 |
Leading Cancer Diagnostics Market Players Strategic Assessments of Major Suppliers and Emerging Market Entrants
| Sep 2009 |
£1,340 |
Cancer Diagnostic Testing Instrumentation Operating Characteristics, Features and Selling Prices of Leading Automated and Semiautomated Analyzers
| Sep 2009 |
£305 |
Competitive Outlook on Lung Cancer Drug Development The Missing Handbook to New Product Planning and Portfolio Planning
| Aug 2009 |
£2,240 |
CHK and KSP/Eg5 Inhibitors Competitor Analysis
| Aug 2009 |
£160 |
Cancer Drug Discoveries: Colorectal Cancer What the future holds
| Jul 2009 |
£1,295 |
PI3K-Akt-mTOR Pathway Inhibitors Competitor Analysis
| Jul 2009 |
£450 |
Pipeline and Commercial Insight: Osteoporosis Novel agents to battle for payer acceptance
| Jul 2009 |
£9,270 |
Attention-Deficit Hyperactivity Disorder Market Forecast
| Jul 2009 |
£9,270 |
Inflammatory Bowel Disease Market Forecast
| Jul 2009 |
£9,270 |
The Vaccines Market Outlook to 2014 Competitive Landscape, Pipeline Analysis, Growth Opportunities and Market Forecasts
| Jul 2009 |
£2,340 |
World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024
| Jul 2009 |
£1,499 |
HDAC Inhibitors Competitor Analysis
| Jul 2009 |
£360 |
Bcr-Abl Kinase Inhibitors Competitor Analysis
| Jul 2009 |
£180 |
Immunotoxins Competitor Analysis
| Jul 2009 |
£135 |
IGF-1R Antagonists Competitor Analysis
| Jul 2009 |
£225 |
Osteoporosis Market Forecast
| Jul 2009 |
£9,270 |
Lymphoma Drug Development Strategies at Work Define Your Competition
| Jun 2009 |
£1,780 |
Asthma and COPD Market Forecast
| Jun 2009 |
£9,270 |
Chinese Markets for Asthma Treatment Drugs
| Jun 2009 |
£2,440 |
Immunocytokines Competitor Analysis
| Jun 2009 |
£135 |
Antibody-Drug Conjugates (ADC) Competitor Analysis
| Jun 2009 |
£225 |
Forecast Insight: HIV Cross-class fixed dose combinations drive continued growth
| Jun 2009 |
£9,270 |
Chinese Markets for Hepatitis Treatment Drugs
| Jun 2009 |
£2,440 |
Aurora Kinase Inhibitors Competitor Analysis
| Jun 2009 |
£160 |
HIV Market Forecast
| Jun 2009 |
£9,270 |
Chinese Markets for Anti-Infectious Disease Drugs
| Jun 2009 |
£2,440 |
Global Diabetes Market
| Jun 2009 |
£3,965 |
MEK Inhibitors Competitor Analysis
| Jun 2009 |
£135 |
Allergy Drug Pipeline and R&D 2009 Emerging Technologies, Companies, Products, Applications, Sales & Market Share, and Worldwide Outlook
| Jun 2009 |
£1,005 |
Chinese Markets for Leukemia Treatment Drugs
| Jun 2009 |
£2,440 |
Chinese Markets for Blood Disease Drugs
| Jun 2009 |
£2,440 |
Advances in Ophthalmology Markets in The Treatment of Eye Disorders and Corrective Vision, 2nd Ediiton
| Jun 2009 |
£2,135 |
Insulin Delivery Devices Market Analysis and Future Forecast
| Jun 2009 |
£520 |
Therapeutic Peptides in Oncology Favorable Conditions But Where to Commercialize?
| May 2009 |
£3,235 |
The Toolkit for Diabetes MSL Programs
| May 2009 |
£4,760 |
Chronic Obstructive Pulmonary Disease (COPD) Market: An Analysis
| May 2009 |
£485 |
World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The
| May 2009 |
£2,435 |
Raf Inhibitors Competitor Analysis
| May 2009 |
£180 |
H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays)
| May 2009 |
£490 |
China Asthma Drug Market Report The Chinese Asthma Drug Drug Utilization
| May 2009 |
£2,785 |
Novel Mitotic Kinase Inhibitors Competitor Analysis
| May 2009 |
£315 |
Elastase Inhibitors Competitor Analysis
| May 2009 |
£180 |
Ras-Raf-MEK-ERK Inhibitors Competitor Analysis
| May 2009 |
£315 |
PARP Inhibitors Competitor Analysis
| Apr 2009 |
£90 |
Prostate Cancer Therapeutics
| Apr 2009 |
£2,410 |
Multiple Myeloma Therapeutics
| Apr 2009 |
£2,410 |
Diabetes, Metabolic Syndrome and Cardiovascular Disease
| Apr 2009 |
£2,105 |
Hepatitis C Virus And Therapeutics
| Apr 2009 |
£2,410 |
Hypoxia-Inducible Factor (HIF) Competitor Analysis
| Apr 2009 |
£90 |
European HIV/AIDS Therapeutics Markets
| Apr 2009 |
£3,965 |
Blood Glucose Testing and Diabetes Management
| Apr 2009 |
£2,105 |
Leukemia A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking
| Apr 2009 |
£1,780 |
Sphingosine-1-Phosphate (S1P) Competitor Analysis
| Apr 2009 |
£90 |
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry
| Apr 2009 |
£6,950 |
Looking at the Cancer Therapy Market
| Apr 2009 |
£425 |
Alzheimer's Disease: Markets, Pipeline and Opportunities 2009
| Apr 2009 |
£1,855 |
Future of the Diabetes Care Devices Market to 2015
| Mar 2009 |
£2,135 |
CD3 Antagonists Competitor Analysis
| Mar 2009 |
£180 |
The Global Multiple Sclerosis Market 2009-2024
| Mar 2009 |
£1,499 |
Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment
| Mar 2009 |
£180 |
China Allergy Drug Market Report The Chinese Allergy Cancer Drug Utilization
| Mar 2009 |
£2,785 |
Global Alzheimer Drugs Market An Analysis
| Mar 2009 |
£425 |
Stakeholder Opinions: Physician perception of biologics in autoimmune disease - Targeted detailing is the key to success Healthcare
| Mar 2009 |
£2,315 |
Opportunities Assessment for Hepatitis B Therapeutics Market in Indonesia
| Mar 2009 |
£3,660 |
China Senile Dementia Drug Market Report The Chinese Dementia Drug Utilization
| Mar 2009 |
£4,950 |
Stakeholder Opinions: Cystic Fibrosis - A pipeline full of hope Healthcare
| Mar 2009 |
£2,315 |
Amyotrophic Lateral Sclerosis/ Lou Gehrig's disease Competitor Analysis
| Mar 2009 |
£180 |
Stakeholder Insight: Psoriasis - Biologics are yet to make topical treatments obsolete Healthcare
| Mar 2009 |
£8,070 |
p38 MAPK Inhibitors Competitor Analysis
| Mar 2009 |
£180 |
Stakeholder Opinions: Pancreatic Cancer - Gemzar dominance will continue among high levels of persistent unmet needs Healthcare
| Mar 2009 |
£2,315 |
Multiple Sclerosis Treatment Market Opportunities for Oral Drugs
| Mar 2009 |
£485 |
Attention-Deficit Hyperactivity Disorder (ADHD) Competitor Analysis
| Mar 2009 |
£180 |
EpCAM Antagonists Competitor Analysis
| Mar 2009 |
£90 |
Global HIV Market: An Analysis
| Feb 2009 |
£425 |
TNF Antagonists & Agonists Competitor Analysis
| Feb 2009 |
£270 |
Chinese Markets for Prostate Cancer Treatment Drugs
| Feb 2009 |
£2,440 |
Chinese Markets for Breast Cancer Treatment Drugs
| Feb 2009 |
£2,440 |
Chinese Markets for Lung Cancer Treatment Drugs
| Feb 2009 |
£2,440 |